Methods of treating psoriasis with anti-TNF antibodies

Details Methods of treating psoriasis with anti-TNF antibodies Methods of treating psoriasis with anti-TNF antibodies

2007-03-20

2007-03-20

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S133100, C424S141100, C424S158100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388230

Reexamination Certificate

active

09927703

ABSTRACT:
The invention relates to anti-TNF antibodies, fragments, regions and derivatives thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in methods of treating psoriasis, as well as polynucleotides coding for murine and chimeric anti-TNF antibodies, and methods of producing anti-TNF antibodies, fragments, regions and derivatives thereof.

REFERENCES:
patent: 4603106 (1986-07-01), Cerami et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4822776 (1989-04-01), Cerami et al.
patent: 5075236 (1991-12-01), Yone et al.
patent: 5223395 (1993-06-01), Gero
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5342613 (1994-08-01), Creaven et al.
patent: 5360716 (1994-11-01), Ohmoto et al.
patent: 5436154 (1995-07-01), Barbanti et al.
patent: 5654407 (1997-08-01), Boyle et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5698195 (1997-12-01), Le et al.
patent: 5700788 (1997-12-01), Mongelli et al.
patent: 5730975 (1998-03-01), Hotamisligil et al.
patent: 5741488 (1998-04-01), Feldman et al.
patent: 5750105 (1998-05-01), Newman et al.
patent: 5776947 (1998-07-01), Kroemer et al.
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 5958413 (1999-09-01), Anagnostopulos et al.
patent: 5959087 (1999-09-01), Rathjen et al.
patent: 5993833 (1999-11-01), DeLacharriere et al.
patent: 5994510 (1999-11-01), Adair et al.
patent: 6015558 (2000-01-01), Hotamisligil et al.
patent: 6172202 (2001-01-01), Marcucci et al.
patent: 6190691 (2001-02-01), Mak
patent: 6194451 (2001-02-01), Alpegiani et al.
patent: 6309640 (2001-10-01), Cerami et al.
patent: 6419927 (2002-07-01), Cerami et al.
patent: 0212489 (1987-03-01), None
patent: 0218868 (1987-04-01), None
patent: 0260610 (1988-03-01), None
patent: 0 288 088 (1988-10-01), None
patent: 0288088 (1988-10-01), None
patent: 0308378 (1989-03-01), None
patent: 0 351 789 (1990-01-01), None
patent: 0350690 (1990-01-01), None
patent: 0351789 (1990-01-01), None
patent: 0380068 (1990-08-01), None
patent: 0393438 (1990-10-01), None
patent: 0398327 (1990-11-01), None
patent: 0412486 (1991-02-01), None
patent: 0433900 (1991-06-01), None
patent: 0 453 898 (1991-10-01), None
patent: 0526905 (1993-02-01), None
patent: 0 585 705 (1994-03-01), None
patent: 0 614 984 (1994-09-01), None
patent: 0101681 (1994-12-01), None
patent: 0 663 836 (1995-07-01), None
patent: 0 706 795 (1996-04-01), None
patent: 0 706 795 (1997-12-01), None
patent: 0 861 850 (1998-09-01), None
patent: 0 867 509 (1998-09-01), None
patent: 0 869 179 (1998-10-01), None
patent: 0 870 827 (1998-10-01), None
patent: 0486526 (2001-03-01), None
patent: 0486526 (2001-03-01), None
patent: 61-047500 (1986-03-01), None
patent: 02-227095 (1990-09-01), None
patent: WO 89/08460 (1989-09-01), None
patent: 90/00902 (1990-02-01), None
patent: WO 90/01950 (1990-03-01), None
patent: WO91/02078 (1991-02-01), None
patent: WO 91/04054 (1991-04-01), None
patent: 91/09967 (1991-06-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO91/09967 (1991-07-01), None
patent: WO92/01059 (1992-01-01), None
patent: WO 92/01472 (1992-02-01), None
patent: WO 92/16553 (1992-03-01), None
patent: WO92/07076 (1992-04-01), None
patent: WO 92/02190 (1992-06-01), None
patent: WO92/02190 (1992-06-01), None
patent: WO 92/11383 (1992-07-01), None
patent: WO92/13095 (1992-08-01), None
patent: 92/16553 (1992-10-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 93/11236 (1993-06-01), None
patent: WO 94/08609 (1994-04-01), None
patent: WO 94/08619 (1994-04-01), None
patent: WO98/51344 (1998-11-01), None
patent: WO00/62790 (2000-10-01), None
Fundamental Immunology, Third Edition, edited by Paul, Raven Press, NY, 1993; p. 242.
Whittle, Nigel, et al., “Construction and Expression of a CDR-Grafted Anti-TNF Antibody,”J. Cell Biochem, Supl. 13A:96 (1989).
Gorman, S.D. and Clark, M.R., “Humanisation of monoclonal antibodies for therapy,”Sem Immunol, 2:457-466 (1990).
Starnes, H. Fletcher, Jr., et al., “ANTI-IL-6 Monoclonal Antibodies Protect Against LethalEscherichia coliInfection and Lethal Tumor Necrosis Factor∝ Challenge in Mice,”J. Immunol, 145:4185-4191 (1990).
Duncombe, Andrew S. et al., “Tumor Necrosis Factor Mediates Autocrine Growth Inhibition in a Chronic Leukemia,”J Immunol, 143:3828-3834 (1989).
Aderka, Dan et al., “IL-6 Inhibits Lipopolysaccharide-Induced tumor Necrosis Factor Production in Cultured Human Monocytes, U937 Cells, and in Mice,”J Immunol, 143:3517-3523 (1989).
Aderka, Dan, “Role of Tumor Necrosis Factor in the Pathogenesis of Intravascular Coagulopathy of Sepsis: Potential New Therapeutic Implications,”Isr J Med Sci, 27:52-60 (1991).
Lassalle, Ph., et al., “Potential Implicaton of Endothelial Cells in Bronchial Asthma,”Int Arch Allergy Appl Immunol, 94:233-238 (1991).
Fong, Yuman and Lowry, Stephen F., “Tumor Necrosis Factor in the Pathophysiology of Infection and Sepsis,”Clin Immunol Immunopathol, 55:157-170 (1990).
Eck, Michael J. and Sprang, Stephen R., “The Structure of Tumor Necrosis Factor—∝ at 2.6 Å Resolution,”J Biol Chem, 264:17595-17605 (1989).
Gillies, Stephen D. et al., “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes,”J Immunol Methods, 125:191-202 (1989).
Kameyama, Koh-zoh, et al., “Convenient plasmid vectors for construction of chimeric mouse/human antibodies,”FEBS Lett, 244:301-306 (1989).
Hayashi, H. et al., “An Enzyme-linked Immunosorbent Assay for Recombinant Human Tumor Necrosis Factor Using Monoclonal Antibody,”Recent Adv. Chemother, 820-821 (1985).
Hirai, Makoto et al., “Production and characterization of monoclonal antibodies to human tumor necrosis factor,”J Immunol Methods, 96:57-62 (1987).
Sunahara, N. et al., “Simple enzyme immunoassay methods for recombinant human tumor necrosis factor ∝ and its antibodies using a bacterial cell wall carrier,” J Immunol Methods, 109:203-214 (1988).
Oliff, A., et al., “Tumors Secreting Human TNF/Cachetin Induce Cachexia in Mice,”Cell, 50:555-563 (1987).
Mule, J.J., et al., “Antitumor Activity of Recombinant Interleukin 6 in Mice,”The Journal of Experimental Medicine, 171:629-636 (1990).
Luettig, B., et al., “Evidence For The Existence Of Two Forms Of Membrane Tumor Necrosis Factor: An Integral Protein And A Molecule Attached To Its Receptor,”The Journal of Immunology, 143:4034-4038 (1989).
Barbuto, J.A.M., et al., “Production of neutralizing antibodies to tumor necrosis factor by human tumor-infiltrating B lymphocytes,”Proceedings of the American Association for Cancer Research, 34:487, Abstract 2904, (1993).
Bendtzen, K., et al., “Auto-Antibodies to IL-1α and TNFα In Normal Individuals And In Infectious And Immunoinflammatory Disorders,”The Physiological and Pathological Effects of Cytokines, 10B:447-452 (1990).
Fomsgaard, A., et al., “Auto-Antibodies To Tumour Necrosis Factor α In Healthy Humans And Patients With Inflammatory Diseases And Gram-Negative Bacterial Infections,”Scand. J. Immunol., 30:219-223 (1989).
James, K. and Bell, G.T., “Human Monoclonal Antibody Production Current Status And Future Prospects,”Journal of Immunological Methods, 100:5-40 (1987).
Alberts, B., et al., Molecular Biology of the Cell, Garland Publishing Inc., pp. 182-183 (1983).
Simpson, S.Q., et al., “Role Of Tumor Necrosis Factor In Sepsis And Acute Lung Injury,”Critical Care Clinics, 5:27-47 (1989).
Bendtzen, K., et al., “Native inhibitors (autoantibodies) of IL-1α and TNF,”Immunology Today, 10(7):222 (1989).
Davenport, C., et al., “Stimulation Of Human B Cells Specific ForCandida albicansFor Monoclonal Antibody Production,”FEMS Microbiol Immunol, 4(6):335-343 Abstract (1992).
Pennica, D., et al., “Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin

Affiliated with

Also associated with

Rating

Methods of treating psoriasis with anti-TNF antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating psoriasis with anti-TNF antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating psoriasis with anti-TNF antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3777077